search
Back to results

Comparison of Dual-mode ER:YAG Laser in Patients With Long Keloid/Hypertrophic Scars (KELOID)

Primary Purpose

Keloid, Hypertrophic Scars

Status
Withdrawn
Phase
Phase 2
Locations
Study Type
Interventional
Intervention
Laser coagulation
Laser w/o coagulation
Sponsored by
Insel Gruppe AG, University Hospital Bern
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Keloid focused on measuring Keloid, Hypertrophic scars, Er-YAG Lasers

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Given written informed consent
  • Skin type I-IV
  • Presence of long keloid/hypertrophic scar of at least 3 cm² and of uniform/symmetric type
  • Willingness and ability to adhere study protocol

Exclusion Criteria

  • History of adverse events related to ablative fractional laser therapy
  • Ablative resurfacing within the last 6 months on the scar
  • Oral retinoid, any immunosuppressive treatments in the last 6 months
  • Pregnancy, lactation

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Active Comparator

    Active Comparator

    Arm Label

    Laser coagulation

    Laser w/o coagulation

    Arm Description

    Er:YAG laser treatment with coagulation modality

    Er:YAG laser treatment without coagulation modality

    Outcomes

    Primary Outcome Measures

    Any reduction from baseline of scars volume as assessed by image analysis

    Secondary Outcome Measures

    Any reduction from baseline of scars volume as assessed by image analysis
    Any improvement of scars as assessed by physician according to an ordinal 6-points scale
    Overall patient satisfaction to the proposed therapy as assessed by visual analogue scale
    Erythema index as assessed by image analysis
    Hypopigmentation as assessed by image analysis

    Full Information

    First Posted
    September 2, 2015
    Last Updated
    April 12, 2017
    Sponsor
    Insel Gruppe AG, University Hospital Bern
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT02546076
    Brief Title
    Comparison of Dual-mode ER:YAG Laser in Patients With Long Keloid/Hypertrophic Scars
    Acronym
    KELOID
    Official Title
    Within-subject Randomized Clinical Trial Comparing Dual-mode ER:YAG Laser in Patients With Long Keloid/Hypertrophic Scars
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    April 2017
    Overall Recruitment Status
    Withdrawn
    Why Stopped
    Lack of patients
    Study Start Date
    May 2016 (Actual)
    Primary Completion Date
    January 2017 (Actual)
    Study Completion Date
    January 2017 (Actual)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    Insel Gruppe AG, University Hospital Bern

    4. Oversight

    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    Skin injuries due to trauma are relatively common, and patients are very concerned about scars caused by trauma and primary repair. Recently, the use of ablative and non-ablative lasers based on the fractional approach has become a novel strategy for the treatment of scars. The objective of this study is to compare the efficacy of dual-mode Er:YAG laser delivering pulses either with and without heat/coagulation in a cohort of patients with long keloid/hypertrophic scars. The main hypothesis is that ablative fractional laser without heat/coagulation is equivalent to laser with heat/coagulation in terms of scars volume reduction, while the secondary hypothesis is that ablative fractional laser without heat/coagulation is superior in terms of post-operative erythema and hypopigmentation reduction.
    Detailed Description
    Background Skin injuries, such as lacerations or abrasions, due to trauma are relatively common, and patients are very concerned about scars caused by trauma and primary repair. Multiple modalities for improving the clinical appearance of scars have been attempted with varying success, including corticosteroids, dermabrasion, surgical revision, chemical peeling, silicone gel application, pressure therapy, and radiation. Lasers such as the carbon dioxide (CO2), erbium: yttrium-aluminum-garnet (Er:YAG), and pulsed dye (PDL) lasers have all been used with differing success in the treatment of scars. The goal of all these treatments is to soften depressions and stimulate neocollagenesis in order to fill in the residual defects. Ablative lasers used for skin resurfacing, such as the CO2 and Er:YAG laser, can reduce various scars, but significant adverse effects limit their use, and patient downtime can be extensive. Owing to these potential risks, nonablative lasers have been developed as a safe alternative to ablative laser resurfacing, and have been reported to be effective and safe for scars. However outcomes have remained unsatisfactory and require several treatments to achieve satisfactory efficacy. Recently, the use of ablative and non-ablative lasers based on the fractional approach has become a novel strategy for the treatment of scars, and some authors have suggested that treatment with fractional lasers for various scars, such as postoperative, atrophic, and acne scars, has been demonstrated to safely improve the appearance of the scars. However, there is a lack of studies comparing coagulation modality of such lasers. Objective The objective of this study is to compare the efficacy of dual-mode Er:YAG laser delivering pulses either with and without heat/coagulation in a cohort of patients with long keloid/hypertrophic scars. Methods This is a single center, investigator initiated, double blind, within-subject split-lesion design, equivalence randomized clinical study. Consecutive patients, referring to Dermatology outpatient and fulfilling inclusion criteria, are included. Participants are then randomly assigned to get treatment with Er:YAG laser on half of scar section side by equally splitting the lesion area in two symmetric and uniform parts. One side will be treated with coagulation while the other one will be without. In case of multiple lesions per patient, only the largest and most uniform one is selected for the study purpose.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Keloid, Hypertrophic Scars
    Keywords
    Keloid, Hypertrophic scars, Er-YAG Lasers

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Phase 2
    Interventional Study Model
    Parallel Assignment
    Masking
    ParticipantOutcomes Assessor
    Allocation
    Randomized
    Enrollment
    0 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    Laser coagulation
    Arm Type
    Active Comparator
    Arm Description
    Er:YAG laser treatment with coagulation modality
    Arm Title
    Laser w/o coagulation
    Arm Type
    Active Comparator
    Arm Description
    Er:YAG laser treatment without coagulation modality
    Intervention Type
    Device
    Intervention Name(s)
    Laser coagulation
    Intervention Description
    The treatment consists in performing Er:Yag laser with long-pulsed Erbium mode
    Intervention Type
    Device
    Intervention Name(s)
    Laser w/o coagulation
    Intervention Description
    The treatment consists in performing Er:Yag laser with true pulsed Erbium mode
    Primary Outcome Measure Information:
    Title
    Any reduction from baseline of scars volume as assessed by image analysis
    Time Frame
    24 weeks
    Secondary Outcome Measure Information:
    Title
    Any reduction from baseline of scars volume as assessed by image analysis
    Time Frame
    4, 8, 12, 16, 24 weeks
    Title
    Any improvement of scars as assessed by physician according to an ordinal 6-points scale
    Time Frame
    4, 8, 12, 16, 24 weeks
    Title
    Overall patient satisfaction to the proposed therapy as assessed by visual analogue scale
    Time Frame
    16, 24 weeks
    Title
    Erythema index as assessed by image analysis
    Time Frame
    4, 8, 12, 16, 24 weeks
    Title
    Hypopigmentation as assessed by image analysis
    Time Frame
    4, 8, 12, 16, 24 weeks

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Given written informed consent Skin type I-IV Presence of long keloid/hypertrophic scar of at least 3 cm² and of uniform/symmetric type Willingness and ability to adhere study protocol Exclusion Criteria History of adverse events related to ablative fractional laser therapy Ablative resurfacing within the last 6 months on the scar Oral retinoid, any immunosuppressive treatments in the last 6 months Pregnancy, lactation
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Maurice Adatto, MD
    Organizational Affiliation
    Dep. of Dermatology, Inselspital University Hospital, Bern (Switzerland)
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Learn more about this trial

    Comparison of Dual-mode ER:YAG Laser in Patients With Long Keloid/Hypertrophic Scars

    We'll reach out to this number within 24 hrs